Food Allergy Resources

Current Clinical Trial Studies Involving Peanut Allergy

Peanut Allergy Study - Clinical Trial List

Study 1:
Title: Oral Immunotherapy (OIT) for Peanut Allergy
Recruitment: Active, not recruiting
Study Results: No Results Available
Conditions: Peanut Hypersensitivity
Interventions: Other: Peanut flour | Other: Subjects will receive oral oat flour.
Sponsors: Duke University
Gender: Both
Age Groups: Child
Phases: Phase II
Start Date: June 2009
Completion Date: November 2013
Primary Completion Date: November 2012
Outcome Measures: To treat peanut-allergic subjects with peanut OIT and to determine whether this protocol lowers their risk of anaphylactic reactions and causes long-term tolerance. | To determine the molecular-level effect that peanut OIT has on the peanut-specific cellular and humoral activity/response in peanut-allergic subjects.
URL: http://ClinicalTrials.gov/show/NCT00815035

Study 2:
Title: A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy
Recruitment: Active, not recruiting
Study Results: No Results Available
Conditions: Peanut Hypersensitivity | Food Hypersensitivity|Immediate Hypersensitivity
Interventions: Drug: Peanut powder | Drug: Peanut extract|Drug: Placebo extract|Drug: Placebo powder
Sponsors: Johns Hopkins University
Gender: Both
Age Groups: Child|Adult
Phases: Phase I|Phase II
Start Date: March 2010
Completion Date: January 2013
Primary Completion Date: January 2012
Outcome Measures: The primary endpoint is to determine if sublingual administration of peanut extract and oral administration of peanut powder can induce a 10-fold increase in tolerance as measured by food challenge. | The incidence of all serious adverse events on peanut SLIT and peanut OIT. | To assess any changes in clinical and mechanistic endpoints. | Peanut tolerance, as determined by oral food challenge (OFC) after being off daily SLIT and OIT for 4 weeks.
URL: http://ClinicalTrials.gov/show/NCT01084174

Study 3:
Title: Persistence of Oral Tolerance to Peanut
Recruitment: Enrolling by invitation
Study Results: No Results Available
Conditions: Peanut Allergy
Interventions:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)
Gender: Both
Age Groups: Child
Start Date: May 2011
Completion Date: February 2015
Primary Completion Date: February 2015
Outcome Measures: Proportion of participants with peanut allergy at year 6 in the group who consumed peanut and the group who avoided peanut in the LEAP Study. | Proportion of participants with peanut allergy at year 6 in the group who consumed peanut in the LEAP Study. | Proportion of subjects with allergic sensitization to selected ingested and inhaled allergens, and with seasonal rhino-conjunctivitis, perennial rhinoconjunctivitis, and asthma. | Incidence of adverse events, and nutritional evaluations. | Results of cellular and humoral assessments of immune response related to the development of allergy or tolerance to specific allergens.
URL: http://ClinicalTrials.gov/show/NCT01366846

Study 4:
Title: Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy
Recruitment: Not yet recruiting
Study Results: No Results Available
Conditions: Peanut Allergy
Interventions: Drug: QGE031|Drug: Placebo
Sponsors: Novartis Pharmaceuticals
Gender: Both
Age Groups: Adult
Phases: Phase II
Start Date: November 2011
Completion Date:
Primary Completion Date: February 2013
Outcome Measures: The increase in the threshold dose of peanut protein that includes objective hypersensitivity reactions after treatment assessed by double-blind, placebo-controlled food challenges (DBPCFC) before and after 16 weeks of treatment. | The percentage of patients that experienced an increase from baseline to the end of treatment period in the threshold dose of at least 2 steps (or 10 fold) increase in peanut dose in the DBPCFC after 16 weeks of treatment. | The mean number of steps improved from baseline threshold dose of peanut protein in the DBPCFC after 16 weeks of treatment. | The shift in the mean cumulative doses in peanut protein in the DBPCFC before exhibiting an objective allergic reaction after 16 weeks of treatment.|From baseline, 8, 15, and 29 days (each a treatment day) and every four weeks thereafter, measure blood level of QGE031 (Pharmacokinetics) | From baseline, 8, 15, and 29 days (each a treatment day) and every four weeks thereafter, measure blood level of total IgE (Pharmacodynamics) | From baseline, 8, 15, and 29 days (each a treatment day) and every four weeks thereafter, measure blood level of free IgE (Pharmacodynamics)
URL: http://ClinicalTrials.gov/show/NCT01451450

Study 5:
Title: Mucosal Immunotherapy for Peanut Allergy
Recruitment: Active, not recruiting
Study Results: No Results Available
Conditions: Food Hypersensitivity
Interventions: Other: Peanut flour | Dietary Supplement: Oat|Other: Peanut flour
Sponsors: Duke University | University of Arkansas
Gender: Both
Age Groups: Child
Start Date: March 2007
Completion Date: December 2012
Primary Completion Date: December 2012
Outcome Measures: An outcome measure will be determined by a comparison of the result of the double blind placebo controlled food challenges (DBPCFC) at the starting point and at the end of the study for each of the subjects. | Other outcome measures will be the changes seen in the pre and post peanut skin tests and the pre and post IgE levels to peanut
URL: http://ClinicalTrials.gov/show/NCT00597675

Study 6:
Title: Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy
Recruitment: Recruiting
Study Results: No Results Available
Conditions: Peanut Hypersensitivity
Interventions: Drug: Peanut Oral Immunotherapy|Drug: Omalizumab
Sponsors: Duke University | Genentech
Gender: Both
Age Groups: Child | Adult | Senior
Phases: Phase I | Phase II
Start Date: July 2009
Completion Date: July 2014
Primary Completion Date: July 2014
Outcome Measures: The percentage of subjects who pass the 20gm peanut flour (~50% peanut protein) oral food challenge following the desensitization phase of the study. | Incidence of side effects during initial escalation and build up phase.
URL: http://ClinicalTrials.gov/show/NCT00932282

Study 7:
Title: Epicutaneous Immunotherapy in Peanut Allergy in Children
Recruitment: Active, not recruiting
Study Results: No Results Available
Conditions: Peanut Allergy
Interventions: Biological: Epicutaneous Immunotherapy | Biological: placebo of peanut
Sponsors: Assistance Publique - Hôpitaux de Paris | DBV Technologies
Gender: Both
Age Groups: Child
Phases: Phase II
Start Date: August 2010
Completion Date: December 2012
Primary Completion Date: October 2012
Outcome Measures: Proportion of patients able to consume >1000 mg of peanut proteins symptom-free. | Description of the level of Ig. | Proportion of patients able to consume >1000 mg of peanut proteins symptom-free. | Proportion of patients able to consume >1000 mg of peanut proteins symptom-free. | Diameter and safety
URL: http://ClinicalTrials.gov/show/NCT01197053

Study 8:
Title: Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy
Recruitment: Recruiting
Study Results: No Results Available
Conditions: Peanut Allergy
Interventions: Biological: Whole peanut extract | Biological: Placebo formulation
Sponsors: DBV Technologies
Gender: Both
Age Groups: Child | Adult
Phases: Phase I
Start Date: July 2010
Completion Date: October 2011
Primary Completion Date: September 2011
Outcome Measures: Safety evaluation | Systemic reactions evaluation and treatment; treatment adherence
URL: http://ClinicalTrials.gov/show/NCT01170286

Study 9:
Title: Mucosal Immunotherapy for Peanut Allergy in Young Children
Recruitment: Active, not recruiting
Study Results: No Results Available
Conditions: Food Hypersensitivity
Interventions: Other: Peanut and placebo flour | Other: Peanut protein flour
Sponsors: Duke University
Gender: Both
Age Groups: Child
Phases: Phase I | Phase II
Start Date: June 2009
Completion Date: December 2014
Primary Completion Date: June 2014
Outcome Measures: To treat peanut-allergic subjects with PMIT and to determine whether this protocol lowers their risk of anaphylactic reactions and causes long-term tolerance. | To determine the effect that PMIT has on the peanut-specific cellular and humoral response in peanut-allergic subjects.
URL: http://ClinicalTrials.gov/show/NCT00932828

Study 10:
Title: Promoting Tolerance to Peanut in High-Risk Children
Recruitment: Active, not recruiting
Study Results: No Results Available
Conditions: Peanut Allergy | Eczema | Egg Allergy | Food Allergy
Interventions: Dietary Supplement: Age appropriate peanut snack | Behavioral: Peanut avoidance
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID) | Immune Tolerance Network (ITN)
Gender: Both
Age Groups: Child
Start Date: December 2006
Completion Date: July 2014
Primary Completion Date: July 2014
Outcome Measures: Proportion of participants with peanut allergy at 60 months of age. | Effect of peanut consumption or avoidance on other allergy outcomes|safety of peanut consumption among study participants. | Immunologic mechanisms by which consumption of a peanut-containing snack may induce tolerance to peanuts
URL: http://ClinicalTrials.gov/show/NCT00329784

Study 11:
Title: Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults
Recruitment: Active, not recruiting
Study Results: No Results Available
Conditions: Food Hypersensitivity | Hypersensitivity | Immediate Hypersensitivity | Peanut Hypersensitivity
Interventions: Biological: E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID) | Allertein Therapeutics, LLC | Consortium of Food Allergy Research
Gender: Both
Age Groups: Adult
Phases: Phase I
Start Date: October 2009
Completion Date: September 2011
Primary Completion Date: September 2011
Outcome Measures: Percentage of participants who successfully complete the dosage regimen with no more than mild symptoms related to EMP-123 dosing. | Occurrence of adverse events|Rate of desensitization, as determined by peanut endpoint titration prick test in peanut allergic participants|Change in basophil activation. | Decreased Type 2 helper T cell peanut-induced T-lymphocyte phenotype and increased T-lymphocyte regulatory phenotype|Increase in peanut-specific immunoglobulin (IgG4) and IgA. | Decrease in peanut-specific IgE
URL: http://ClinicalTrials.gov/show/NCT00850668

Study 12:
Title: Immunotherapy for Peanut Allergy
Recruitment: Completed
Study Results: No Results Available
Conditions: Allergy
Interventions: Procedure: Sublingual immunotherapy
Sponsors: Duke University
Gender: Both
Age Groups: Child | Adult
Start Date: April 2006
Completion Date: May 2011
Primary Completion Date: May 2011
Outcome Measures: A negative double-blind placebo controlled food challenge at the completion the two years of the study. | A change in the cytokine level between the baseline and each selected time point during the two years of the study.
URL: http://ClinicalTrials.gov/show/NCT00429429

Study 13:
Title: Peanut Sublingual Immunotherapy
Recruitment: Active, not recruiting
Study Results: No Results Available
Conditions: Food Hypersensitivity | Hypersensitivity | Immediate Hypersensitivity | Peanut Hypersensitivity
Interventions: Drug: Peanut powder | Drug: Placebo for peanut powder
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)|Consortium of Food Allergy Research
Gender: Both
Age Groups: Child | Adult
Phases: Phase I | Phase II
Start Date: December 2007
Completion Date: June 2014
Primary Completion Date: December 2010
Outcome Measures: Percentage of desensitized participants (while on daily SLIT) as measured by the 5 gm OFC or a 10-fold increase in the amount of peanut powder, compared to baseline oral food challenge (OFC)|Percentage of participants who tolerate the buildup stage to the planned maintenance dose of peanut SLIT. | Peanut tolerance, as determined by OFC after being off daily SLIT for 8 weeks including differences in immunologic measures versus desensitized participants. | Incidence of all serious adverse events|Changes in immunologic laboratory values
URL: http://ClinicalTrials.gov/show/NCT00580606

Study 14:
Title: Oral Peanut Immunotherapy
Recruitment: Recruiting
Study Results: No Results Available
Conditions: Peanut Allergy
Interventions: Dietary Supplement: Peanut flour OIT
Sponsors: Massachusetts General Hospital
Gender: Both
Age Groups: Child | Adult
Start Date: March 2011
Completion Date: March 2014
Primary Completion Date: August 2012
Outcome Measures: Tolerance | Desensitization | The frequency of side-effects and their relationship to other variables | A significantly lower frequency of accidental ingestion reactions compared to controls | A longitudinal suppression of end-point skin testing by 2 log dilution. | A longitudinal suppression of peanut-specific basophil activation by 1.5 log dilution | A longitudinal doubling of peanut-specific IgG4 | A longitudinal increase of Ara h 2-specific IgG+ B cells by >1.5 SD
URL: http://ClinicalTrials.gov/show/NCT01324401

Study 15:
Title: Omalizumab in the Treatment of Peanut Allergy
Recruitment: Active, not recruiting
Study Results: No Results Available
Conditions: Food Allergy | Peanut Allergy
Interventions: Drug: omalizumab
Sponsors: Johns Hopkins University | National Institute of Allergy and Infectious Diseases (NIAID)
Gender: Both
Age Groups: Adult
Phases: Phase II
Start Date: July 2009
Completion Date: August 2011
Primary Completion Date: August 2011
Outcome Measures: Proportion of participants who have a four-fold increase in the dose of peanut protein needed to induce positive challenge (with final threshold dose >1000 mg) at the 6 month oral food challenge. | Reduction of peanut-allergen induced basophil histamine release in vitro in subjects treated with omalizumab. | Changes in dose of peanut protein needed to induce a positive challenge at the second oral food challenge compared to baseline. | Changes in skin test reactivity on omalizumab therapy and up to 6 months during drug withdrawal. | Changes in free and total peanut-specific IgE and total IgE as well as the ratio of peanut-specific IgE to total IgE on omalizumab therapy and up to 6 months after drug withdrawal. | Changes in basophil markers CD203c, CD63, CD69/ST2, and basogranulin, as well as tryptase during oral food challenges on omalizumab therapy. | Changes in the indirect effects of serum on basophil histamine release on omalizumab therapy and up to 6 months after drug withdrawal.
URL: http://ClinicalTrials.gov/show/NCT00949078

Study 16:
Title: Understanding How the Immune System Responds to Viruses in Peanut Allergic Children Undergoing Peanut Oral Immunotherapy
Recruitment: Enrolling by invitation
Study Results: No Results Available
Conditions: Peanut Allergy
Interventions: Other: Peanut flour
Sponsors: University of Texas Southwestern Medical Center
Gender: Both
Age Groups: Child
Start Date: February 2010
Completion Date: January 2018
Primary Completion Date: January 2018
Outcome Measures: We will measure changes in the immune system on a molecular level affected by viral infections in peanut allergic children undergoing peanut OIT. | We will determine if our peanut OIT protocol lowers the risk of anaphylaxis in peanut allergic children.
URL: http://ClinicalTrials.gov/show/NCT01074840

Study 17:
Title: Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance
Recruitment: Recruiting
Study Results: No Results Available
Conditions: Peanut Hypersensitivity | Food Hypersensitivity | Food Allergy | Peanut Allergy
Interventions: Drug: Liquid peanut extract
Sponsors: Duke University | National Institute of Allergy and Infectious Diseases (NIAID) | National Center for Complementary and Alternative Medicine (NCCAM)
Gender: Both
Age Groups: Child
Phases: Phase I | Phase II
Start Date: June 2011
Completion Date: June 2021
Primary Completion Date: December 2017
Outcome Measures: Percentage of subjects on placebo vs peanut SLIT who pass the 54 month double blind, placebo controlled food challenge to assess tolerance. | Percentage of subjects who demonstrate clinical desensitization by passing the 48 month double-blind, placebo-controlled food challenge. | Induction of clinical tolerance after 48months vs 60 months of peanut SLIT.|The change in immune parameters over time associated with the induction of clinical tolerance versus the failure to achieve clinical tolerance.
URL: http://ClinicalTrials.gov/show/NCT01373242

Study 18:
Title: Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults
Recruitment: Recruiting
Study Results: No Results Available
Conditions: Peanut Allergy
Interventions: Drug: powdered peanut protein
Sponsors: Duke University
Gender: Both
Age Groups: Adult
Phases: Phase II|Phase III
Start Date: December 2010
Completion Date:
Primary Completion Date: September 2014
Outcome Measures: To treat peanut-allergic subjects with POIT and to determine whether this protocol lowers their risk of anaphylactic reactions and causes long-term tolerance. | To determine the effect that POIT has on the peanut-specific cellular and humoral response in peanut-allergic subjects.
URL: http://ClinicalTrials.gov/show/NCT01274429

Study 19:
Title: An Observational Study of Childhood Food Allergy
Recruitment: Active, not recruiting
Study Results: No Results Available
Conditions: Food Hypersensitivity | Peanut Hypersensitivity | Egg Hypersensitivity | Milk Hypersensitivity
Interventions:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)|Consortium of Food Allergy Research
Gender: Both
Age Groups: Child
Start Date: July 2006
Completion Date: July 2016
Primary Completion Date: July 2016
Outcome Measures:
URL: http://ClinicalTrials.gov/show/NCT00356174

Study 20:
Title: Xolair Enhances Oral Desensitization in Peanut Allergic Patients
Recruitment: Recruiting
Study Results: No Results Available
Conditions: Peanut Allergy
Interventions: Other: omalizumab, oral desensitization
Sponsors: Children's Hospital Boston
Gender: Both
Age Groups: Child | Adult
Phases: Phase I | Phase II
Start Date: February 2011
Completion Date: January 2013
Primary Completion Date: January 2013
Outcome Measures: ability of a patient to tolerate rapid oral peanut desensitization to a dose of 500 mg peanut (cumulative dose, 1,000 mg). | Ability of a patient to tolerate rapid oral peanut desensitization to a dose of 4,000 mg of peanut.
URL: http://ClinicalTrials.gov/show/NCT01290913

Study 21:
Title: A Safety and Efficacy Study of Xolair in Peanut Allergy
Recruitment: Terminated
Study Results: http://clinicalstudyresults.gene.com/q2788g.pdf
Conditions: Allergy
Interventions: Drug: Xolair (omalizumab)
Sponsors: Genentech
Gender: Both
Age Groups: Child | Adult | Senior
Phases: Phase II
Start Date: June 2004
Completion Date:
Last Updated: February 28, 2007
Last Verified: February 2007
Primary Completion Date:
Outcome Measures:
URL: http://ClinicalTrials.gov/show/NCT00086606

Study 22:
Title: The Effect of Extrinsic Factors on Food Allergy
Recruitment: Not yet recruiting
Study Results: No Results Available
Conditions: Peanut Hypersensitivity
Interventions: Other: Food challenge
Sponsors: Cambridge University Hospitals NHS Foundation Trust|Imperial College London
Gender: Both
Age Groups: Adult
Phases: Phase II
Start Date: February 2012
Completion Date: February 2015
Primary Completion Date: January 2015
Outcome Measures: Minimum amount of peanut protein in milligrams which causes an objective clinical reaction during peanut challenges
URL: http://ClinicalTrials.gov/show/NCT01429896

Study 23:
Title: Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders
Recruitment: Recruiting
Study Results: No Results Available
Conditions: Food Hypersensitivity | Eosinophilia | Peanut Hypersensitivity
Interventions:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)
Gender: Both
Age Groups: Adult
Start Date: August 2010
Completion Date:
Primary Completion Date:
Outcome Measures:
URL: http://ClinicalTrials.gov/show/NCT01212016

Study 24:
Title: Study of Tolerance to Oral Peanut
Recruitment: Active, not recruiting
Study Results: No Results Available
Conditions: Peanut Allergy
Interventions: Dietary Supplement: Peanut oral immunotherapy
Sponsors: Cambridge University Hospitals NHS Foundation Trust
Gender: Both
Age Groups: Child
Phases: Phase I
Start Date: January 2008
Completion Date: January 2012
Primary Completion Date: January 2012
Outcome Measures: Pass/fail peanut challenge
URL: http://ClinicalTrials.gov/show/NCT01259804

Study 25:
Title: Development of an Algorithm to Better Predict Clinical Responsiveness to Peanut
Recruitment: Recruiting
Study Results: No Results Available
Conditions: Peanut Hypersensitivity
Interventions: Procedure: allergy skin testing | Procedure: venepuncture
Sponsors: Hamilton Health Sciences Corporation | Food Allergy Initiative | AllerGen NCE Inc.
Gender: Both
Age Groups: Child | Adult | Senior
Phases:
Start Date: September 2002
Completion Date:
Primary Completion Date:
Outcome Measures:
URL: http://ClinicalTrials.gov/show/NCT00243555

Study 26:
Title: A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g
Recruitment: Completed
Study Results: http://clinicalstudyresults.gene.com/q3623g.pdf
Conditions: Peanut Hypersensitivity
Interventions: Drug: omalizumab
Sponsors: Genentech
Gender: Both
Age Groups: Child | Adult | Senior
Phases: Phase II
Start Date: November 2006
Completion Date:
Primary Completion Date: June 2008
Outcome Measures: Serious Adverse Events | Food Allergen Exposure, Assessed on Patient-reported Questionnaire | Food-allergic Reactions As Assessed by the Ewan Scale | Nonserious Food-related Adverse Events (AEs) and Other Nonserious AEs
URL: http://ClinicalTrials.gov/show/NCT00382148

Study 27:
Title: Trichuris Suis Ova in Peanut and Tree Nut Allergy
Recruitment: Recruiting
Study Results: No Results Available
Conditions: Food Allergy
Interventions: Drug: Trichuris suis ova (TSO)
Sponsors: Beth Israel Deaconess Medical Center | Food Allergy Initiative
Gender: Both
Age Groups: Adult
Phases: Phase I
Start Date: February 2010
Completion Date: December 2011
Primary Completion Date: December 2011
Outcome Measures: Occurrence of unexpected severe side effects
URL: http://ClinicalTrials.gov/show/NCT01070498

Study 28:
Title: Peanut Oral Immunotherapy
Recruitment: Active, not recruiting
Study Results: No Results Available
Conditions: Food Hypersensitivity
Interventions: Other: Peanut flour
Sponsors: Duke University | University of Arkansas
Gender: Both
Age Groups: Child
Phases:
Start Date: March 2003
Completion Date: July 2012
Primary Completion Date: July 2012
Outcome Measures: Subject will pass a double blind placebo food challenge (DBPCFC) at the end of the study and a second food challenge 1 month later after being off of peanut for 1 month. | IgE to peanut will decrease below a level of 2
URL: http://ClinicalTrials.gov/show/NCT00598039

Study 29:
Title: Double Blind Peanut Sublingual Immunotherapy
Recruitment: Active, not recruiting
Study Results: No Results Available
Conditions: Food Hypersensitivity
Interventions: Other: Peanut protein | Other: Glycerol saline drops | Other: Blood draw and skin tests
Sponsors: Duke University
Gender: Both
Age Groups: Child
Phases:
Start Date: January 2008
Completion Date: December 2014
Primary Completion Date: December 2014
Outcome Measures: Subject will successfully pass a double blind placebo controlled food challenge at the end of the study after having been off the sublingual immunotherapy for 2 to 4 weeks. | The peanut specific IgE will have decreased from the level at the start of the study.
URL: http://ClinicalTrials.gov/show/NCT00597727

Study 30:
Title: Evaluation and Long-Term Follow-Up of Patients With Allergic and Inflammatory Disorders
Recruitment: Recruiting
Study Results: No Results Available
Conditions: Inflammatory Disorder
Interventions:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)
Gender: Both
Age Groups: Child | Adult | Senior
Phases:
Start Date: August 1996
Completion Date:
Last Updated: April 20, 2011
Last Verified: April 2011
Acronym:
Primary Completion Date:
Outcome Measures:
URL: http://ClinicalTrials.gov/show/NCT00557895

Study 31:
Title: Therapeutic Effect of Chinese Herbal Medicine on Food Allergy
Recruitment: Recruiting
Study Results: No Results Available
Conditions: Food Allergy
Interventions: Drug: FAHF-2 (TM)
Sponsors: Li, Xiu-Min, M.D. | National Center for Complementary and Alternative Medicine (NCCAM)
Gender: Both
Age Groups: Child | Adult
Phases: Phase II
Start Date: December 2007
Completion Date: June 2012
Primary Completion Date: May 2012
Outcome Measures: Safety of FAHF-2 | lab studies
URL: http://ClinicalTrials.gov/show/NCT00602160

Study 32:
Title: Evaluation of Food Hypersensitivity in Children/Adolescents With Functional Dyspepsia
Recruitment: Completed
Study Results: No Results Available
Conditions: Dyspepsia
Interventions: Device: in vitro and in vivo allergy testing
Sponsors: Children's Mercy Hospital Kansas City
Gender: Both
Age Groups: Child
Phases: Phase I
Start Date: June 2006
Completion Date: September 2008
Primary Completion Date: September 2008
Outcome Measures: measure specific IgE, IgG total, IgG subclass 4, skin prick tests and atopy patch tests to milk, egg, soy, corn, peanut and wheat. | Determine T-lymphocytes, eosinophils and mast cell densities on duodenal biopsy samples demonstrating eosinophilia.
URL: http://ClinicalTrials.gov/show/NCT00328679

References:
U.S. National Institutes of Health. (October 29, 2011). Clinical Trials. Retrieved October 29, 2011 from http://www.clinicaltrials.gov/.